SAIZEN SUMMARY
Saizen® [somatropin (rDNA origin) for injection] is a human growth hormone produced by recombinant DNA technology.
Pediatric Patients
Saizen® [somatropin (rDNA origin) for injection] is indicated for the long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Adult Patients
Saizen® [somatropin (rDNA origin) for injection] is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria:
Adult Onset: Patients who have growth hormone deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
Childhood Onset: Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.
In general, confirmation of the diagnosis of adult growth hormone deficiency in both groups usually requires an appropriate growth hormone stimulation test. However, confirmatory growth hormone stimulation testing may not be required in patients with congenital/genetic growth hormone deficiency or multiple pituitary hormone deficiencies due to organic disease.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Saizen (Somatropin)
Cost-effectiveness of somatropin for the treatment of short children born small for gestational age. [2010.06]
BACKGROUND: Short children born small for gestational age (SGA) may be at increased risk for long-term morbidity and reduced health-related quality of life (HRQoL) due to their short stature. Normalization of height in childhood and adolescence is possible in such children via the use of the recombinant human growth hormone somatropin. OBJECTIVE: The aim of this study was to determine whether somatropin was a cost-effective treatment option in short children born SGA... CONCLUSION: In this model, somatropin was a cost-effective treatment option for short children born SGA from the perspective of the UK NHS.
Relative bioavailability of two drug products of somatropin obtained from either the milk of transgenic cows or bacterial culture. [2010]
BACKGROUND: Our objective was to assess the relative bioavailability of the first somatropin produced in transgenic cloned cows that carry the human growth hormone (GH) gene (Biohormon) and somatropin produced in Escherichia coli culture (HHT), the procedure most frequently used for the commercial production of the hormone... CONCLUSION: This study demonstrates that a single dose of Biohormon, the first product with somatropin obtained from milk of transgenic mammals, is bioequivalent to the reference product HHT according to standard criteria. Copyright (c) 2010 S. Karger AG, Basel.
Cost-effectiveness of somatropin for the treatment of short children born small
for gestational age. [2010]
cost-effective treatment option in short children born SGA... CONCLUSION: In this model, somatropin was a cost-effective treatment option for
Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. [2009.05]
The inflammation in asthma involves both the large and the small airways. This study was designed to examine whether mometasone delivered from a dry powder inhaler would improve those parameters thought to reflect patency and obstruction of the small airways (diameter <2 mm)... Mometasone delivered by a dry powder inhaler improved asthma control and pulmonary function in tests reflecting both large and small airways.
Clinical Trials Related to Saizen (Somatropin)
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study [Terminated]
To assess the immunogenicity of Saizen® solution for injection in adult subjects with
documented Growth Hormone Deficiency (GHD).
An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) [Recruiting]
This is an open-label, single-arm, multicenter, Phase 4 study to explore the immunogenicity
of the liquid formulation of Saizen® in subjects with Adult Growth Hormone Deficiency
(AGHD), who are growth hormone (GH) treatment-naïve or who had prior GH treatment for GHD
which was stopped at least 1 month prior to Screening and have no contraindication to the
use of GH.
Saizen in Intra-uterine Growth Retardation [Completed]
Study of safety of Saizen® in children born with serious intra-uterine growth retardation
(IUGR) treated to final height. An open, phase III study involving 17 centers in France.
The study enrolled children who have completed 3 or 2 years of treatment and at least one
year of post treatment observation in the Sponsor Studies GF 4001 (Safety and Efficacy of
Saizen in the Treatment of Young Children Born with Severe IUGR) or GF 6283 (Effect of
Intermittent versus Continuous Saizen Therapy in Young Children Born with Severe IUGR),
respectively.
Detailed description: Serious IUGR is a syndrome characterized by low birth length and
weight for gestational age (less than 10 percentile). The secretion of growth hormone in
response to provocative stimuli (e. g. arginine, insulin) is normal in these children. Apart
from low birth weight, children born with IUGR may have minor or major malformations.
A catch-up period with a supraphysiological growth velocity generally occurs during the
first 6 to 24 months of life in 80 to 90 percent (%) of these children. This generally
allows them to reach normal height. That means that conversely, approximately 10 to 20% of
children do maintain a statural handicap. Puberty occurs at a normal age and the retardation
in bone maturation present during the first years of life disappears very quickly. This
leads to short adult stature in subjects who have not shown spontaneous catch-up during the
first years of life. A safe and effective means of promoting growth without accelerating the
timing or tempo of puberty would therefore be desirable.
A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA) [Terminated]
This open, multicentric, randomized, controlled study is planned to evaluate the correlation
between gene expression, spontaneous catch-up growth and therapeutic response to Saizen in
SGA children.
A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS) [Completed]
This is an open-label, multi-center, randomized, two-arm parallel, no-treatment group
controlled (only for the first 6 months), Phase 3 study in children with ISS. The subjects
will be treated with 0. 067 milligram/kilogram/day (mg/kg/day) of Saizen®, weight base dose,
for 12 months (12 months of treatment in the test group, and 6 months of no treatment and
then 6 months of treatment in the control group).
Reports of Suspected Saizen (Somatropin) Side Effects
Pneumonia (14),
Convulsion (13),
Headache (11),
Suicidal Ideation (10),
Fall (9),
Vomiting (9),
Pyrexia (7),
Malaise (7),
Angina Pectoris (7),
Urinary Tract Infection (7), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Saizen has an overall score of 8. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Saizen review by 56 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | adrenal burnout, chronic fatigue & premature agin |
| Dosage & duration: | | 0.16 mg per injection, 6 nights a week taken 6 nights a week for the period of 6 years |
| Other conditions: | | insomnia, brain fog, exhaustion |
| Other drugs taken: | | Armour, T3, hydrocortisone, estradiol, progesterone | | |
Reported Results |
| Benefits: | | More energy and endurance, much more able to concentrate, skin elasticity improved and noticed overall skin rejuvenation and tightening, sleep improved and wake up feeling more rested, aware of vision improvements and improved libido. |
| Side effects: | | None. However it did take a long while to see many of the results, perhaps 3 to 6 months for many of the noticeable effects, even though there was some energy improvement noticed within days. |
| Comments: | | 1 subcutaneous injection of somatropin in abdomen or inner thigh 6 nights a week. |
|
|
|
Page last updated: 2013-02-10
|
